Selected Publications

Chaturvedi A, Herbst L, Pusch S, Klett L, Goparaju R, Stichel D, Kaulfuss S, Panknin O, Zimmermann K, Toschi L, Neuhaus R, Haegebarth A, Rehwinkel H, Hess-Stumpp H, Bauser M, Bochtler T, Struys EA, Sharma A, Bakkali A, Geffers R, Araujo-Cruz MM, Thol F, Gabdoulline R, Ganser A, Ho AD, von Deimling A, Rippe K, Heuser M, Krämer A: Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia (in press) 2017. 

Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, Hinderhofer K, Heilig CE, Kramer M, Thiede C, Benner A, Bornhäuser M, Ehninger G, Ho AD, Jauch A, Krämer A: Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood (in press) 2016.

Konotop G, Bausch E, Nagai T, Turchinovich A, Becker N, Benner A, Boutros M, Mizuno K, Krämer A*, Raab MS: Pharmacological inhibition of centrosome clustering by slingshot-mediated cofilin activation and actin cortex destabilization. *Corresponding author. Cancer Res 76: 6690-6700, 2016.

Löffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, Folprecht G, Stenzinger A, Dietel M, Weichert W, Krämer A: Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget 7: 44322-44329, 2016.

Daly OM, Gaboriau D, Karakaya K, King S, Dantas TJ, Lalor P, Dockery P, Krämer A, Morrison CG: Gene-targeted CEP164-deficient cells show a ciliation defect with intact DNA repair capacity. J Cell Sci 129: 1769-1774, 2016.

Hemminki K, Chen B, Kumar A, Melander O, Manjer J, Hallmans G, Löffler H, Krämer A, Försti A: Germline genetics of cancer of unknown primary (CUP) and its specific subtypes. Oncotarget 7: 22140-22149, 2016. 

Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel W, Kaufmann M, Baldus C, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause S, Serve H, Haenel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke J-M, Platzbecker U, Schaich M, Krämer A, Roellig C, Schetelig J, Bornhäuser M, Ehninger G: Karyotype Complexity and Prognosis in Acute Myeloid Leukemia. Blood Cancer J 6: e386, 2016.

Balss J, Thiede C, Bochtler T, Okun JG, Saadati M, Benner A, Pusch S, Ehninger G, Schaich M, Ho AD, von Deimling A, Krämer A*, Heilig CE: Pretreatment D-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. *Corresponding author. Leukemia 30: 782-788, 2016.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut I-M, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia: Addition of sorafenib versus placebo to standard therapy in patients  aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 16: 1691-1699, 2015.

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky W, Schmitz N, Berdel WE, Stelljes M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Schetelig J, Ehninger G; Study Alliance Leukemia (SAL): Allogeneic stem cell transplantation in patients with NPM1 mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of 304 patients after upfront HLA typing within the SAL AML 2003 trial. J Clin Oncol 33: 403-410, 2015.

Alsara M, Löffler H, Fechter A, Bartek J, Krämer A: Cep63 recruits Cdk1 to the centrosome. Cancer Res 75: 777-778, 2015.

Bochtler T, Fröhling S, Krämer A: Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia [Invited spotlight review]. Leukemia 29: 1243-1252, 2015.

Bochtler T, Stölzel F, Heilig CE, Kunz C, Mohr B, Jauch A, Janssen JW, Kramer M, Benner A, Bornhäuser M, Ho AD, Ehninger G, Schaich M, Krämer A. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol. 2013 Nov 1;31(31):3898-905.

Mardin BR, Isokane M, Cosenza MR, Krämer A, Ellenberg J, Fry AM, Schiebel E. EGF-Induced Centrosome Separation Promotes Mitotic Progression and Cell Survival. Dev Cell. 2013 May 13;25(3):229-40.

Löffler H, Fechter A, Liu FY, Poppelreuther S, Krämer A. DNA damage-induced centrosome amplification occurs via excessive formation of centriolar satellites. Oncogene. 2013 Jun 13;32(24):2963-72.

Vulprecht J, David A, Tibelius A, Castiel A, Konotop G, Liu F, Bestvater F, Raab MS, Zentgraf H, Izraeli S, Krämer A. STIL is required for centriole duplication in human cells. J Cell Sci. 2012 Mar 1;125(Pt 5):1353-62.

Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Krämer A. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res. 2012 Oct 15;72(20):5374-85.

Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, Schwäble J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Göhring G, Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, Kühlcke K, Schlegelberger B, Thrasher AJ, Hoelzer D, Seger R, von Kalle C, Grez M. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature Medicine 16: 198-204, 2010.

Leber B, Maier B, Fuchs F, Chi J, Riffel P, Anderhub S, Wagner L, Ho AD, Salisbury JL, Boutros M, Krämer A: Proteins required for centrosome clustering in cancer cells. Science Translational Medicine 26: 33ra38, 2010.

Tibelius A, Marhold J, Zentgraf H, Heilig CE, Neitzel H, Ducommun B, Rauch A, Ho AD, Bartek J, Krämer A: Microcephalin and pericentrin regulate mitotic entry via centrosome-associated Chk1. Journal of Cell Biology 2009; 185: 1149-1157.

Krämer A, Reiter A, Kruth J, Erben P, Hochhaus A, Muller M, Cross NC, Jones AV, Ho AD, Hensel M. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007 Jul;8(7):658-60.

Rebacz B, Larsen TO, Clausen MH, Rønnest MH, Löffler H, Ho AD, Krämer A. Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res. 2007 Jul 1;67(13):6342-50.

Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland J, Lukas C, Ørntoft T, Lukas J, Bartek J: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870, 2005.

Krämer A, Mailand N, Lukas C, Syljuasen RG, Wilkinson CJ, Nigg EA, Bartek J, Lukas J. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol. 2004 Sep;6(9):884-91.

Neben K, Giesecke C, Schweizer S, Ho AD, Krämer A. Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic risk profile. Blood. 2003 Jan 1;101(1):289-91. Epub 2002 Jun 28.

to top